Skip to main content

Investors

Ulisse Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.

About Us

We are technology leaders in distribuited and connected diagnostics


Investors

The Ulysses Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.


02 September, 2020

Scientific publications

Impact of lockdown on Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America


This study analyzed how lockdown strategies and testing capacity influenced COVID-19's Case Fatality Rate (CFR) and viral mutations in seven countries in Europe and North America. After normalizing CFR for each country's PCR testing capability, the study found that strict lockdown policies combined with widespread testing were correlated with a significant decline in the death rate. Genomically, a specific pattern of mutations stabilized by April 2020. A novel mutation in the spike protein was detected exclusively in Sweden, a country that enacted a soft lockdown strategy.

Pachetti et al., Journal of Translational Medicine | 2020